T1DM Therapy Development Service

T1DM Therapy Development Service

The destruction of insulin-producing β-cells is the main pathophysiological feature of T1DM. Ace Therapeutics can provide researchers engaged in drug development of diabetes with more efficient function analysis and overall therapy services.

Mechanism of the suppressive action of T cell lymphocytes in T1DMMechanism of the suppressive action of T cell lymphocytes in T1DM (Ben-skowronek, I.; et al. International Journal of Molecular Sciences, 2021)

Gene Targets of T1DM

Two HLA class II haplotypes involved in antigen presentation, HLA-DR and HLA-DQ, are linked to approximately 50% of disease heritability.

Our Services

Molecule biology research provides more options for diabetes treatment options. With the goal of scientific research of diabetes, Ace Therapeutics can provide a full set of services. Our services include but not limited to the followings.

  • Target Prediction and Verification
    The mutation sites that lead to disease phenotypes are obtained through the Whole Genome Resequencing, and then relevant cell or animal models are constructed for verification.

Features of Our Services

Highly CustomizableHighly Customizable

One-stop ServicesOne-stop Services

High QualityHigh Quality

Professional TeamProfessional Team

Ace Therapeutics offers cost-effect and high-quality research services related to T1DM therapy development for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us.


  1. Ben-skowronek, I.; et al. Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1. International Journal of Molecular Sciences. 2021, 23(1), 390.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
Related Products
Contact Info
Copyright © Ace Therapeutics. All Rights Reserved.